Aeglea Biotherapeutics Has Potential In Rare Diseases; We Remain Neutral [Seeking Alpha]
Aeglea BioTherapeutics, Inc. (AGLE)
Last aeglea biotherapeutics, inc. earnings: 8/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aegleabio.com/investor-overview
Company Research
Source: Seeking Alpha
Aeglea Biotherapeutics Has Potential In Rare Diseases; We Remain Neutral Summary AGLE is developing treatment for an ultrarare disease, ARG1 deficiency in children. The company has just enough cash until 2020. While we like the science, we prefer to sit on the sidelines on this one for the time being. Aeglea Biotherapeutics ( Catalyst There is no real near term catalyst. Data from the phase 3 PEACE study will be released in late 2021. However, INDs from its other pipeline candidates, publication of phase 1/2 data etc could be minor catalysts before the main event two years down the line. Previous trial data reported including AGLE’s pegzilarginase, a pegylated, cobalt-substituted human arginase 1, was able to effectively and sustainably lower plasma arginine levels. Below is an excerpt from the company’s presentation at the 2018 American Society of Human Genetics (ASHG) Conference. Methods: Data are from an ongoing Phase 1/2 clinical trial and Phase 2 Open Label Extension study of int
Show less
Read more
Impact Snapshot
Event Time:
AGLE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGLE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGLE alerts
High impacting Aeglea BioTherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics